Pegylated interferon
Pegylated interferon (PEG-IFN) is a class of medication that includes three different drugs as of 2012:[1]
- Pegylated interferon-alpha-2a
- Pegylated interferon-alpha-2b
- Pegylated interferon-beta-1a[2]
In these formulations, Polyethylene glycol (PEG) is added to make interferon last longer in the body.[3] They are used to treat both hepatitis B,[4] hepatitis C[1] and multiple sclerosis.[2]
Pegylated interferon is contraindicated in patients with hyperbilirubinaemia.
References
- ^ a b editor, Emilio Jirillo, (2008). Hepatitis C virus disease : immunobiology and clinical applications ([Online-Ausg.] ed.). New York: Springer. p. 237. ISBN 978-0-387-71375-5.
{{cite book}}:|last=has generic name (help)CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link) - ^ a b Kieseier BC, Calabresi PA.; Calabresi (2012). "PEGylation of Interferon-β-1a: A Promising Strategy in Multiple Sclerosis". CNS Drugs. 26 (3): 205–14. doi:10.2165/11596970-000000000-00000. PMID 22201341.
- ^ http://www.medscape.com/viewarticle/407963_5 Hepatology Focus: Update on Hepatitis C Treatment: Pegylated Interferon
- ^ Clinical Hepatology. [S.l.]: Springer Berlin Heidelberg. 2010. p. 765. ISBN 978-3-642-04509-7.
{{cite book}}:|first=missing|last=(help)
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |